Intrepid Financial Planning Group’s Actinium Pharmaceuticals ATNM Stock Holding History

Intrepid Financial Planning Group’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.5K	Hold	10,500	–	–	﹤0.01%	124
2025 Q4	$14.3K	Sell	10,500 -2,000	-16%	-$2.92K	0.01%	121
2025 Q3	$20K	Hold	12,500	–	–	0.01%	128
2025 Q2	$17.5K	Sell	12,500 -2,000	-14%	-$2.99K	0.01%	122
2025 Q1	$23.3K	Buy	14,500 +500	+4%	+$635	0.01%	117
2024 Q4	$17.6K	Sell	14,000 -5,000	-26%	-$7.76K	0.01%	121
2024 Q3	$35.7K	Sell	19,000 -1,000	-5%	-$3.95K	0.02%	125
2024 Q2	$148K	Buy	20,000 +4,000	+25%	+$32.9K	0.06%	118
2024 Q1	$125K	Hold	16,000	–	–	0.05%	119
2023 Q4	$81.3K	Sell	16,000 -2,000	-11%	-$10.3K	0.04%	117
2023 Q3	$107K	Hold	18,000	–	–	0.06%	112
2023 Q2	$134K	Sell	18,000 -1,000	-5%	-$8.51K	0.06%	113
2023 Q1	$180K	Sell	19,000 -1,000	-5%	-$10.6K	0.09%	109
2022 Q4	$213K	Hold	20,000	–	–	0.12%	96
2022 Q3	$148K	Hold	20,000	–	–	0.08%	96
2022 Q2	$96K	Buy	+20,000	New	+$114K	0.05%	103

Other funds holding ATNM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Intrepid Financial Planning Group's ATNM Position: Q1 2026 in Review

Intrepid Financial Planning Group held its Actinium Pharmaceuticals (ATNM) position steady in Q1 2026 at 10,500 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #124.

Intrepid Financial Planning Group first reported a position in ATNM in Q2 2022 and has held it in 16 quarters since. The position peaked at $213K in Q4 2022. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

Intrepid Financial Planning Group held 10,500 shares of Actinium Pharmaceuticals worth $10.5K as of Q1 2026.
Intrepid Financial Planning Group left its Actinium Pharmaceuticals share count unchanged in Q1 2026.
Actinium Pharmaceuticals made up ﹤0.01% of Intrepid Financial Planning Group's portfolio in Q1 2026, its #124 holding.
Intrepid Financial Planning Group first reported a position in Actinium Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
Intrepid Financial Planning Group's Actinium Pharmaceuticals position peaked at $213K in Q4 2022.
54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Intrepid Financial Planning Group's 13F filing for Q1 2026, filed 13 May 2026.